and Adcirca (tadalafil; also sold by Eli Lilly as Cialis for erectile dysfunction) tablets. Remodulin is approved for both subcutaneous (SC) and intravenous (IV) use. UTHR sits at a Zacks Rank #3 ...

It doesn't matter your age or experience: taking full advantage of the stock market and investing with confidence are common goals for all investors. Luckily, Zacks Premium offers several different ...

Q3 sales in weight loss drugs Mounjaro and Zepbound were more than 20% lower than consensus analyst forecasts, spooking investors.

Concerns about Lilly's Q3 update are overblown. Lilly's impressive growth story remains intact. The stock's valuation is attractive, factoring in anticipated growth over the next several years.

Eli Lilly (LLY) shares tumble in pre-market trading after missing third quarter earnings estimates and cutting its guidance as sales of GLP-1 weight-loss drugs fall short of Wall Street expectations.

Eli Lilly’s Third Quarter Earnings Miss and Forecast Cut Lead to Sharp Stock Drop INDIANAPOLIS (AP) — Eli Lilly is dialing back its 2024 forecast after underwhelming Wall Street with third ...

(Reuters) -Eli Lilly's high profile weight-loss and diabetes drugs fell short of Wall Street sales estimates on Wednesday as supplies sat in warehouses, a 180-degree turn for the company after long ...

Eli Lilly has said it is prepared to invest £279 million ($364 million) in the UK and work with the government to tackle serious public health challenges, including obesity. The proposal ...

Eli Lilly is just weeks away from launching Mounjaro in the UK, after getting approval from medicines regulator, the MHRA, for a new formulation of the drug as a treatment for diabetes and obesity.

Although erectile dysfunction (ED) is a common impairment among older men, its etiology is poorly understood, and cross-sectional studies concerning associations with modifiable behavioral risk ...

Its effects can last up to four hours, and it’s safe to take once per day. Generic name tadalafil, Cialis was approved in Europe in 2002 and in the United States in 2003. While it works similarly to ...

Wall Street analysts are wondering whether the appetite for new diabetes and weight-loss drugs is waning after Eli Lilly lowered its financial forecasts for the year on Wednesday. Sales of its ...